1.03
3.74%
-0.04
アフターアワーズ:
1.02
-0.01
-0.97%
前日終値:
$1.07
開ける:
$1.07
24時間の取引高:
1.39M
Relative Volume:
1.11
時価総額:
$194.60M
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-0.6319
EPS:
-1.63
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
-24.82%
1か月 パフォーマンス:
-26.95%
6か月 パフォーマンス:
-41.31%
1年 パフォーマンス:
+113.91%
Nektar Therapeutics Stock (NKTR) Company Profile
名前
Nektar Therapeutics
セクター
電話
(415) 482-5300
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
NKTR | 1.03 | 194.60M | 90.12M | -276.06M | -193.47M | -1.63 |
VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-05-10 | アップグレード | Jefferies | Underperform → Hold |
2023-02-24 | ダウングレード | Jefferies | Hold → Underperform |
2022-08-08 | ダウングレード | JP Morgan | Neutral → Underweight |
2022-05-31 | 再開されました | Jefferies | Hold |
2022-04-18 | ダウングレード | Goldman | Neutral → Sell |
2022-03-15 | ダウングレード | Cowen | Outperform → Market Perform |
2022-03-15 | ダウングレード | Mizuho | Buy → Neutral |
2022-03-14 | ダウングレード | BTIG Research | Buy → Neutral |
2022-03-14 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-03-14 | ダウングレード | Stifel | Buy → Hold |
2022-03-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
2022-03-09 | アップグレード | Oppenheimer | Perform → Outperform |
2021-11-08 | アップグレード | The Benchmark Company | Hold → Buy |
2021-09-10 | 開始されました | BofA Securities | Neutral |
2021-06-28 | アップグレード | Stifel | Hold → Buy |
2021-05-18 | 再開されました | Goldman | Neutral |
2021-02-22 | ダウングレード | The Benchmark Company | Buy → Hold |
2021-01-06 | 開始されました | Stifel | Hold |
2020-09-14 | 開始されました | JP Morgan | Neutral |
2020-06-10 | ダウングレード | CFRA | Hold → Sell |
2020-05-12 | 繰り返されました | H.C. Wainwright | Neutral |
2020-04-22 | 開始されました | The Benchmark Company | Buy |
2020-03-30 | アップグレード | Goldman | Sell → Neutral |
2020-03-04 | 開始されました | Barclays | Overweight |
2020-02-03 | アップグレード | Mizuho | Neutral → Buy |
2019-10-24 | 開始されました | Oppenheimer | Perform |
2019-10-08 | ダウングレード | Goldman | Buy → Sell |
2019-08-09 | ダウングレード | JP Morgan | Overweight → Neutral |
2019-08-09 | ダウングレード | Jefferies | Buy → Hold |
2019-08-09 | ダウングレード | Mizuho | Buy → Neutral |
2019-03-15 | 開始されました | SVB Leerink | Mkt Perform |
2018-12-13 | 開始されました | Goldman | Buy |
2018-06-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2018-06-04 | 繰り返されました | H.C. Wainwright | Buy |
2018-04-20 | 開始されました | Seaport Global Securities | Buy |
2018-04-13 | 再開されました | Piper Jaffray | Overweight |
2018-04-06 | 繰り返されました | Mizuho | Buy |
2018-04-02 | 再開されました | H.C. Wainwright | Buy |
すべてを表示
Nektar Therapeutics (NKTR) 最新ニュース
Nektar presents preclinical data on NKTR-422 at ACR conference - TipRanks
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence - Longview News-Journal
Eventide Asset Management's Strategic Acquisition of Nektar Ther - GuruFocus.com
Deep Track Capital, LP Reduces Stake in Nektar Therapeutics - GuruFocus.com
Multiple Catalysts Ahead For Nektar Therapeutics (NASDAQ:NKTR) - Seeking Alpha
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance
Nektar Therapeutics to sell Alabama facility to Ampersand - MSN
NKTR-255 Shows Promise for Reversing Radiation-Induced Lymphopenia in NSCLC - Targeted Oncology
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Canada Finance
Nektar Therapeutics (NASDAQ:NKTR) Q3 2024 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Nektar Therapeutics progresses with key clinical studies By Investing.com - Investing.com UK
Nektar Therapeutics (NKTR) Quarterly 10-Q Report - Quartz
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus - Yahoo Finance
Nektar reports NKTR-255 boosts lymphocyte recovery By Investing.com - Investing.com Australia
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook - Yahoo Finance
Nektar: Q3 Earnings Snapshot - The Washington Post
Nektar Therapeutics Reports Stable Q3 Earnings for 2024 - TipRanks
Nektar Therapeutics Q3 2024 Earnings: Revenue Surpasses Estimate - GuruFocus.com
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Nektar: Q3 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria
Nektar Therapeutics (NKTR) Tops Q3 EPS by 2c - StreetInsider.com
Nektar Therapeutics Narrows Losses, Sells Manufacturing Facility for $90M in Q3 | NKTR Stock News - StockTitan
Nektar Therapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Nektar releases promising phase 2 results for NKTR-255 in lymphopenia - MSN
Rx Rundown: Avid Biosciences, Novo Nordisk, Zealand Pharma and more - MM+M Online
Nektar reports NKTR-255 boosts lymphocyte recovery - Investing.com
Nektar Therapeutics (NKTR) and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 - StreetInsider.com
Nektar's NKTR-255 Shows Breakthrough Results in Cancer Treatment Study with MD Anderson | NKTR Stock News - StockTitan
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook By GuruFocus - Investing.com Canada
Nektar Therapeutics to Participate in Upcoming Investor Conferences - Longview News-Journal
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale - Yahoo Finance
Ampersand’s Acquisition of a Nektar’s Manufacturing Facility and Reagent Supply Business - Global Legal Chronicle
Nektar sells its PEGylation reagent manufacturing business - The Pharma Letter
Nektar divests manufacturing site and reagent arm for $90M - Endpoints News
Nektar announces agreement to sell Alabama manufacturing facility and reagent supply business - MSN
NKTRNektar Therapeutics Latest Stock News & Market Updates - StockTitan
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential - Benzinga
Nektar pads wallet with $90M manufacturing plant sale to Ampersand - FiercePharma
Nektar divests Alabama facility to Ampersand for $90 million By Investing.com - Investing.com Canada
Nektar Therapeutics Sells Manufacturing Facility for $90M - TipRanks
Nektar divests Alabama facility to Ampersand for $90 million - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Piper Sandler - MarketBeat
Nektar Therapeutics (NKTR) to Sell Commercial PEGylation Reagent Manufacturing Business in Alabama - StreetInsider.com
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama - StockTitan
Piper Sandler Starts Nektar Therapeutics (NKTR) at Overweight - StreetInsider.com
Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics for $90 million. - Marketscreener.com
Nektar Therapeutics (NKTR) Stock Surges Amidst Mixed Financials - GuruFocus.com
Nektar Therapeutics (NKTR) Scheduled to Post Earnings on Thursday - MarketBeat
Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets - Longview News-Journal
Nektar Therapeutics (NKTR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):